Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Plus Ramucirumab in Metastatic Gastric or GEJ Adenocarcinoma
NCT04632459Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Jun 2021
- Primary completion
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, ramucirumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Samsung Medical Center. Started Jun 2021; status: completed.
02
Drugs
pembrolizumabramucirumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04632459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04632459.